COMPANY PROFILE

Lipum

Develops a biological drug for treatment of chronic inflammatory diseases

Umeå kommun, SwedenFounded 2010Biotech & Life Sciences

Valuation $36M Market cap · 2026

Revenue $2K Latest reported FY

About Lipum

Lipum AB, headquartered in Umeå, Sweden, is an innovative biotech startup focused on developing groundbreaking treatments for chronic inflammatory disorders. The company is pioneering a novel approach to address these conditions, which include diseases like rheumatoid arthritis and Crohn's disease. Chronic inflammatory disorders are long-lasting conditions characterized by persistent inflammation, which can lead to severe health issues and significantly impact the quality of life.

Lipum's primary clientele includes healthcare providers, pharmaceutical companies, and patients suffering from chronic inflammatory diseases. The company operates within the global biopharmaceutical market, which is highly competitive and driven by the constant need for new and effective treatments.

The business model of Lipum revolves around research and development (R&D) of new therapeutic solutions. The company has successfully secured significant funding, including a €2.2 million grant from the European Commission's Horizon 2020 program. This financial support has been crucial in advancing their research and achieving key milestones.

Lipum generates revenue through multiple channels. Primarily, it aims to license its proprietary technology and treatments to larger pharmaceutical companies. Additionally, the company may enter into strategic partnerships and collaborations, which can provide upfront payments, milestone payments, and royalties based on the success of the developed treatments.

In summary, Lipum AB is a biotech startup dedicated to revolutionizing the treatment of chronic inflammatory disorders. By focusing on innovative R&D and leveraging strategic partnerships, the company is well-positioned to make a significant impact in the biopharmaceutical market.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2010
Headquarters: Umeå kommun, Sweden
Listing: IPO 2021
Employees: 13
Open positions: None listed
Dealroom signal: 71.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Inflammatory Diseases, Sustainable Development Goals, Biotech and Pharma, Hard Tech, Seal of Excellence EC, Horizon Europe
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Nov 2025	$17M	$17M	Flerie Invest	↗
GRANT✓Other financing	Dec 2024	$0	—	Undisclosed	↗

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$2K	0%	−$8.3M	-462994.5%	−$8.7M	-483278.1%	$0
2025	$2K	0%	−$8.3M	-462994.5%	−$8.7M	-483278.1%	$0
2024	$2K	0%	−$6.6M	-371157.8%	−$6.7M	-375103.7%	$0
2023	$2K	0%	−$4.5M	-249368.7%			$0
2022	$2K	0%	−$4.6M	-256111.9%
2021	$2K	0%	−$6.3M	-352063.4%
2020	$2K	—	−$2.5M	-142281.5%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Lipum website traffic

Latest recorded traffic for Lipum is 2.9K monthly website visits, down 25.6% over the last three months. Lipum's team declined 13.3% over the past year.

Latest monthly visits2.9K 3-month web change-25.6% 1-year team growth-13.3%

Monthly website visitsFeb 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LHLegacy HealthcareBiopharma developing innovative botanical drugs in supportive oncology care and dermatology	Epalinges, Switzerland	Operational	9	$4.3M	$7.5M
NENeuroKaireGenetika+ is developing a tailored medical diagnostic instrument to help doctors cure depression. Genetika+ predicts the best pharmacological treatment for each patient, allowing faster treatment	Kearny, United States	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
SPSynact PharmaConducting research and development in inflammatory disease	Holte, Denmark	Operational
ANAntabioAntabio is a clinical-stage biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO	Labège, France	Operational
SESensorionDeveloping life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss	Montpellier, France	Operational
MTMinoryx TherapeuticsClinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs	Mataró, Spain	Operational
SESea4UsSea4Us is a biopharmaceutical startup specializing in discovering and developing new drugs, leveraging expertise in ion channels and marine biology	Vila do Bispo, Portugal	Operational